Helicobacter Pylori Infection Management Strategies

Helicobacter pylori is a globally prevalent pathogen implicated in chronic gastritis, peptic ulcer disease and gastric malignancies. Management has traditionally relied on antibiotic-based regimens combining acid suppression with two or more antimicrobial agents. However, increasing resistance to clarithromycin, metronidazole and fluoroquinolones has eroded the success of standard triple therapy. In response, clinicians have adopted bismuth-containing quadruple combinations, sequential and concomitant regimens, high-dose dual therapies and susceptibility-guided treatments. The introduction of potent acid inhibitors such as potassium-competitive acid blockers has improved gastric pH control and antibiotic stability, thereby enhancing eradication rates. Non-antibiotic modalities, including sonodynamic therapy and adjunctive probiotics, seek to neutralise key bacterial virulence factors while preserving gut microbiota balance. Tailoring regimens to regional resistance patterns or individual susceptibility testing has become essential. Integrating novel therapeutic approaches with precise diagnostic pathways promises to curb antimicrobial resistance and optimise patient outcomes worldwide.

Research from Nature Portfolio

Recent studies have explored a non-antibiotic sonodynamic approach to H. pylori eradication. In murine models, lecithin-coated polymeric nanoparticles carrying a photosensitiser both neutralised a principal virulence toxin at baseline and, when activated by low-intensity ultrasound, generated reactive oxygen species that inactivated bacterial cells. This strategy achieved reductions in gastric bacterial load comparable to conventional triple therapy yet avoided disruption of commensal microbiota, even promoting beneficial Lactobacillus growth. These findings highlight a promising antimicrobial-free modality capable of mitigating selective pressures that drive drug resistance.

Helicobacter Pylori Infection Management Strategies publication trend

The graph below shows the total number of articles in helicobacter pylori infection management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Triple therapy: A regimen combining two antibiotics with an acid suppressant to eradicate H. pylori.

Bismuth quadruple therapy: A four-component regimen adding bismuth salts to dual antibiotics and acid suppression for resistant infections.

Potassium-competitive acid blocker: A class of gastric acid suppressants that inhibit the proton pump via competitive potassium binding, exemplified by vonoprazan.

Sonodynamic therapy: A treatment using ultrasound-activated sensitiser particles to generate reactive oxygen species that kill pathogens.

Gut microbiota: The community of microorganisms residing in the gastrointestinal tract, whose diversity is influenced by eradication therapies.

References

1. A nanoparticle-based sonodynamic therapy reduces Helicobacter pylori infection in mouse without disrupting gut microbiota. Nature Communications (2024).
2. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology (2022).
3. Helicobacter pylori treatment: antibiotics or probiotics. Applied Microbiology and Biotechnology (2017).
4. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology (2017).